Tumor necrosis factor polymorphism affects transplantation outcome in patients with myelodysplastic syndrome but not in those with chronic myelogenous leukemia, independent of the presence of HLA-DR15

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 12, 2010, Pages 1700-1706

  Newell, Laura F ^a,b   Gooley, Ted ^a,b   Hansen, John A ^a,b   Stirewalt, Derek L ^a,b   Petersdorf, Effie W ^a,b   Deeg, H Joachim ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Hematopoietic cell transplantation; MDS; Non relapse mortality; TNFx

Indexed keywords

HLA DR15 ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BONE MARROW; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CAUCASIAN; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENOTYPE; GRAFT VERSUS HOST REACTION; HAZARD RATIO; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; RELAPSE; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE;

ADULT; COHORT STUDIES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA-DR ANTIGENS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; TUMOR NECROSIS FACTORS;

EID: 78149409305     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.06.003     Document Type: Article

References (35)

1. Klein J., Gutknecht J., Fischer N. The major histocompatibility complex and human evolution (review). Trends Genet 1990, 6:7-11.
2. Battiwalla M., Hahn T., Radovic M., et al. Human leukocyte antigen (HLA) DR15 is associated with reduced incidence of acute GVHD in HLA-matched allogeneic transplantation but does not impact chronic GVHD incidence. Blood 2006, 107:1970-1973.
3. Davidson J.A., Tate D.G., Poulton K.V., et al. HLA-DR15, reduced relapse rate and improved survival after HLA identical sibling hemopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007, 13:493-494.
4. Stern M., Passweg J., Tiercy J.M., et al. Human leukocyte antigen DR15 is associated with reduced relapse rate and improved survival after human leukocyte antigen-identical sibling hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006, 12:1169-1175.
5. Holler E., Kolb H.J., Möller A., et al. Increased serum levels of tumor necrosis factor α precede major complications of bone marrow transplantation. Blood 1990, 75:1011-1016.
6. Wolff D., Roessler V., Steiner B., et al. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept. Bone Marrow Transplant 2005, 35:1003-1010.
7. Saunthararajah Y., Nakamura R., Nam J.M., et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002, 100:1570-1574.
8. Sugimori C., Yamazaki H., Feng X., et al. Roles of DRB1*1501 and DRB1*1502 in the pathogenesis of aplastic anemia. Exp Hematol 2007, 35:13-20.
9. Xiao M., Qiong L., Yan Z., et al. Experimental and clinical characteristics in myelodysplastic syndrome patients with or without the HLA-DR I 5 allele. Hematol Oncol 2010, 28:98-103.
10. Maciejewski J.P., Follmann D., Nakamura R., et al. Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome. Blood 2001, 98:3513-3519.
11. Bouma G., Crusius J.B., Oudkerk P.M., et al. Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles: relevance for inflammatory bowel disease. Scand J Immunol 1996, 43:456-463.
12. Kroeger K.M., Carville K.S., Abraham L.J. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol 1997, 34:391-399.
13. Sharma S., Ghosh B., Sharma S.K. Association of TNF polymorphisms with sarcoidosis, its prognosis and tumour necrosis factor (TNF)-alpha levels in Asian Indians (review). Clin Exp Immunol 2008, 151:251-259.
14. Hirankarn N., Avihingsanon Y., Wongpiyabovorn J. Genetic susceptibility to SLE is associated with TNF-alpha gene polymorphism -863, but not -308 and -238, in Thai population. Int J Immunogenet 2007, 34:425-430.
15. Skoog T., Hamsten A., Eriksson P. Allele-specific chromatin remodeling of the tumor necrosis factor-alpha promoter. Biochem Biophys Res Commun 2006, 351:777-783.
16. Udalova I.A., Richardson A., Denys A., et al. Functional consequences of a polymorphism affecting NF-kappaB p50-p50 binding to the TNF promoter region. Mol Cell Biol 2000, 20:9113-9119.
17. Deeg H.J., Storer B., Slattery J.T., et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 2002, 100:1201-1207.
18. Radich J.P., Gooley T., Bensinger W., et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 2003, 102:31-35.
19. Anderson J.E., Appelbaum F.R., Schoch G., et al. Relapse after allogeneic bone marrow transplantation for refractory anemia is increased by shielding lungs and liver during total body irradiation. Biol Blood Marrow Transplant 2001, 7:163-170.
20. Flowers M.E.D., Vogelsang G.B. Clinical manifestations and natural history. Chronic Graft Versus Host Disease: Interdisciplinary Management 2009, 56-69. Cambridge University Press, New York. G.B. Vogelsang, S.Z. Pavletic (Eds.).
21. Mielcarek M., Martin P.J., Leisenring W., et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003, 102:756-762.
22. Mielcarek M., Storer B.E., Flowers M.E.D., et al. Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007, 13:1160-1168.
23. Petersdorf E.W., Gooley T.A., Anasetti C., et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood 1998, 92:3515-3520.
24. Lin M.-T., Storer B., Martin P.J., et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med 2003, 349:2201-2210.
25. Fisher L.D., van Belle G. Biostatistics: A Methodology for the Health Sciences 1993, Wiley, New York.
26. Middleton P.G., Taylor P.R.A., Jackson G., et al. Cytokine gene polymorphisms associating with severe acute graft-versus-host disease in HLA-identical sibling transplants. Blood 1998, 92:3943-3948.
27. Takahashi H., Furukawa T., Hashimoto S., et al. Contribution of TNF-alpha and IL-10 gene polymorphisms to graft-versus-host disease following allo-hematopoietic stem cell transplantation. Bone Marrow Transplant 2000, 26:1317-1323.
28. Bertinetto F.E., Dall'Omo A.M., Mazzola G.A., et al. Role of non-HLA genetic polymorphisms in graft-versus-host disease after haematopoietic stem cell transplantation. Int J Immunogenet 2006, 33:375-384.
29. Shaw B.E., Maldonado H., Madrigal J.A., et al. Polymorphisms in the TNFA gene promoter region show evidence of strong linkage disequilibrium with HLA and are associated with delayed neutrophil engraftment in unrelated donor hematopoietic stem cell transplantation. Tissue Antigens 2004, 63:401-411.
30. Gersuk G.M., Beckham C., Loken M.R., et al. A role for tumor necrosis factor-a, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol 1998, 103:176-188.
31. Bornhauser M., Storer B., Slattery J.T., et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 2003, 102:820-826.
32. Socié G., Clift R.A., Blaise D., et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of the 4 randomized studies. Blood 2001, 98:3569-3574.
33. Slattery J.T., Clift R.A., Buckner C.D., et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997, 89:3055-3060.
34. Deeg H.J., Storer B.E., Boeckh M., et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant 2006, 12:573-584.
35. Sandmaier B.M., Storb R. Nonmyeloablative therapy and hematopoietic cell transplantation for hematologic disorders. Thomas' Hematopoietic Cell Transplantation 2004, 1164-1176. Blackwell, Oxford, UK. K.G. Blume, S.J. Forman, F.R. Appelbaum (Eds.).